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Biomaterial scaffolds are central to many tissue engineering strategies as they create a space for tissue
growth and provide a support for cell adhesion and migration. However, biomaterial implantation results
in unavoidable injury resulting in an inﬂammatory response, which can impair integration with the host
and tissue regeneration. Toward the goal of reducing inﬂammation, we investigated the hypothesis that a
lentiviral gene therapy-based approach to localized and sustained IL-10 expression at a scaffold could
modulate the number, relative proportions, and cytokine production of inﬁltrating leukocyte populations. Flow cytometry was used to quantify inﬁltration of six leukocyte populations for 21 days
following implantation of PLG scaffolds into intraperitoneal fat. Leukocytes with innate immune functions (i.e., macrophages, dendritic cells, neutrophils) were most prevalent at early time points, while T
lymphocytes became prevalent by day 14. Reporter gene delivery indicated that transgene expression
persisted at the scaffold for up to 28 days and macrophages were the most common leukocyte transduced, while transduced dendritic cells expressed the greatest levels of transgene. IL-10 delivery
decreased leukocyte inﬁltration by 50% relative to controls, increased macrophage IL-10 expression, and
decreased macrophage, dendritic cell, and CD4 T cell IFN-g expression. Thus, IL-10 gene delivery
signiﬁcantly decreased inﬂammation following scaffold implant into the intraperitoneal fat, in part by
modulating cytokine expression of inﬁltrating leukocytes.
Ó 2013 Elsevier Ltd. All rights reserved.
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1. Introduction
Biomaterial scaffolds are central to many tissue-engineering
strategies and are employed to create an environment to promote
regeneration. Scaffolds create a space for tissue growth, support
host cell inﬁltration, and promote vascularization, all of which are
necessary for regeneration of lost or injured tissues. Scaffolds also
function as a platform for cell transplantation, such as islets for
diabetes therapies, retaining the transplanted cells within a deﬁned
anatomical location, and as a support for cell inﬁltration that integrates transplanted cells with the host. Furthermore, scaffolds
may be modiﬁed with biological signals, such as extracellular matrix (ECM) proteins to modulate cell adhesion and migration, or
inductive factors to stimulate or direct tissue growth. The biological
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Northwestern University, 2145 Sheridan Rd./Tech E136, Evanston, IL 60208-3120,
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signals presented within the scaffold are ultimately aimed at
creating an environment for which endogenous or transplanted
progenitor cells can promote regeneration.
The innate immune response to implanted biomaterials plays a
crucial role in the post-injury microenvironment that can determine the extent of regeneration [1,2]. This immune response is
initiated by tissue resident leukocytes, including macrophages and
dendritic cells, which respond to the foreign material by secreting
chemokines that recruit peripheral leukocytes, initially neutrophils
and monocytes, to the implant site [3e5]. Inﬁltrating leukocytes
become activated at the implant, leading to release of proinﬂammatory cytokines, such as IL-1b, TNF-a, and IFN-g [6,7],
which are well known to inhibit tissue regeneration or limit the
survival of transplanted tissue [8,9]. Conversely, up-regulation of
anti-inﬂammatory cytokines such as IL-10 is associated with resolution of inﬂammation [10] and survival of transplanted cells [11].
Thus, modulating the inﬂammatory response has the potential to
enhance regenerative therapies.
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Localized delivery of immunomodulatory factors has emerged
as a strategy for controlling the immune response. Cells and tissues
have been engineered ex vivo to express immunomodulatory factors prior to transplantation, a strategy that has decreased rejection
of cell and organ transplants [12e14]. In addition, tissueengineering scaffolds have been designed to release proteins to
enhance angiogenesis or modulate inﬂammatory cell responses
[15,16]. However, a major hurdle for this approach is protein stability in the delivery system. More recently, gene delivery from
biomaterial scaffolds has been demonstrated as a versatile
approach to target inﬁltrating cells as bioreactors for the localized
production of factors [17]. Furthermore, gene delivery from biomaterials has been shown to transduce leukocytes, providing the
opportunity to directly modulate the innate response [18e20]. For
example, plasmid-mediated production of IL-10 has been shown to
decrease the inﬂammatory response to stem cells in collagen
scaffolds thus increasing stem cell survival [11,21].
In this report, we investigated the hypothesis that a lentiviral
gene therapy-based approach to localized and sustained IL-10
expression could modulate the number, relative proportions, and
cytokine production of leukocyte populations inﬁltrating
poly(lactide-co-glycolide) (PLG) scaffolds. Using ﬂow cytometry,
we quantiﬁed the inﬁltration of six major leukocyte populations
into PLG scaffolds implanted into the intraperitoneal (IP) fat.
Bioluminescence imaging was employed to characterize the level
and duration of transgene expression within PLG scaffolds
implanted with luciferase viruses, while ﬂow cytometry was used
to identify the leukocyte populations expressing the transgene in
scaffolds delivering tdTomato viruses. Finally, ﬂow cytometry was
employed to characterize leukocyte populations and their cytokine
expression within PLG scaffolds following viral IL-10 delivery.
Development of strategies to modulate the inﬂammatory response
has the potential to create a more permissive environment that can
enhance numerous applications within regenerative medicine.
2. Materials and methods
2.1. Animals
Animal studies were performed in accordance with the NIH Guide for the Care
and Use of Laboratory Animals, and protocols were approved by the IACUC at
Northwestern University. Male CD1 mice weighing 19e24 g were acquired from
Charles River and maintained in conventional housing.

2.2. Virus production
DNA encoding for murine IL-10 (Openbiosystems) or Luciferase (Promega) were
cloned into a self-inactivating lentiviral vector [22]. Lentivirus was produced in HEK293T cells grown in DMEM with 10% FBS at 37  C, and 5% CO2. The lentiviral packaging vectors (pMDL-GagPol, pRSV-Rev, pIVS-VSV-G) were co-transfected with the
lentiviral vector into 293T cells using Lipofectamine 2000 (Life Technologies). After
48 h of transfection, the supernatant was collected and ﬁltered (0.45 micron). Viruses were then concentrated using PEG-it (System Biosciences) and suspended
using sterile PBS. The virus titer was determined using a qPCR Lentivirus Titer Kit
(Applied Biological Materials). Typical titers ranged between 2  109 and
8  109 particles/mL.
2.3. Scaffold fabrication
Poly(lactide-co-glycolide) (PLG) microspheres were prepared as previously
described [23,24]. Brieﬂy, PLG (75:25 mol ratio D,L-lactide to glycolide, 0.76 dL/g)
(Lakeshore Biomaterials) was dissolved in dichloromethane to make a 6% (w/w)
solution, which was then emulsiﬁed in 1% poly(vinyl alcohol) to create microspheres. The microspheres were collected by centrifugation, washed with deionized
water, and lyophilized overnight. Microspheres were combined in a 1:30 ratio with
NaCl particles 250e425 mm diameter. The mixture was pressed in a steel die at
1500 pounds per square inch (psi) and gas-foamed after equilibration to 800 psi
under CO2 gas. Salt particles were removed by immersion in deionized water with
repeated washing. Scaffolds were sterilized in 70% ethanol and then washed twice in
sterile phosphate buffered saline (PBS; Life Technologies). 2  107 viral particles (in
PBS 2e10 mL) were added to the scaffold using a micropipette. Scaffolds were
immediately frozen on dry ice and stored in 80  C freezer until implantation.
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2.4. In vitro cell studies
Scaffolds loaded with virus were seeded with murine RAW 264.7 macrophages
(ATCC) and incubated for 4 h at 37  C. Scaffolds were then transferred into wells
containing fresh media and imaged daily. Luciferase expression was measured by
adding d-luciferin (1 mM; Caliper) to the well 4 h before imaging on the IVIS
Spectrum (Caliper). The signal intensity was reported as an integrated light ﬂux
(photons/s) as determined by Living Image Software (Caliper).
For cytokine production assays, scaffolds loaded with virus were seeded with
RAW 264.7 macrophages and cultured for 3 days prior to the addition of lipopolysaccharide (100 ng/ml; Sigma). Twenty-four hours after addition of lipopolysaccharide, supernatants were collected. TNF-a and IL-10 production was measured by
ELISA (R&D systems).

2.5. Scaffold implantation
Mice received bilateral scaffold implants in the IP fat as previously described
[25]. Brieﬂy, mice were anesthetized with an IP injection of ketamine (10 mg/kg) and
xylazine (5 mg/kg), and the abdominal midline was shaved and prepped in a sterile
fashion. A midline lower abdominal incision was made, and the intraperitoneal (IP)
fat pads were identiﬁed. Scaffolds were wrapped in the right and left IP fat pads,
which were then inserted back into the IP cavity. Following scaffold implant, the
abdominal wall was closed with a running stitch and the skin was closed with
wound clips.

2.6. Flow cytometry
The following antibodies were purchased from Biolegend: anti-CD45 clone 30F11; anti-CD8a clone 53-6.7; anti-Gr1 clone RB6-8C5; anti-F4/80 clone BM8; anti-IL10 clone JES5-16E3; anti-TNF-a clone MP6-XT22; and anti-IFN-g clone XMG1.2. The
following antibodies were purchased from eBioscience: anti-CD11b clone M1/70;
anti-CD11c clone N418; and anti-IL-1b clone NJTEN3.
Following euthanization, scaffolds were harvested and immediately washed in
ice cold Hanks Balanced Salt Solution (HBSS; Life Technologies). Scaffolds were
minced and incubated in collagenase (Roche) at 37  C for 20 min. The solution was
then passed through a 70 mm ﬁlter, washed in HBSS, and suspended in antibodies
against extracellular antigens. After extracellular antibody incubation, cells were
washed to remove unbound antibody. In experiments where intracellular antigens
were detected, cells were then incubated with ﬁxation buffer (eBioscience) and
permeabilization buffer (eBioscience) as per the manufacturer’s instructions. Cells
were then incubated with antibodies to intracellular antigens. After intracellular
antibody incubation, cells were washed to remove unbound antibody and analyzed
on an LSRFortessa ﬂow cytometer (BD Biosciences; San Jose, CA, USA). The entire
sample from each scaffold was collected. Data was analyzed in FlowJo software
(Treestar). Isotype controls were used to set gates for immunophenotyping and cells
isolated from luciferase virus loaded scaffolds were used to set the gate for cells
positive for tdTomato expression.
The gating scheme for ﬂow cytometry data is depicted in Sup. Fig. 1. Cellular
events were gated using forward scatter and side scatter (Sup. Fig. 1A). Leukocytes
were then identiﬁed by CD45 expression (Sup. Fig. 1B). Non-viable cells were then
excluded using LIVE/DEAD viability dye (Life Technologies) (Sup. Fig. 1C). CD4 positive cells (Q1) and CD8 positive cells (Q3) were then identiﬁed based on isotype
controls (Sup. Fig. 1F). These cells are referred to as CD4 T cells and CD8 T cells,
respectively. Cells negative for both CD4 and CD8 were then gated using Gr1 and F4/
80 (Sup. Fig. 1E). Cells positive for Gr1 (Q1) are referred to as neutrophils and F4/80
positive cells (Q2 and Q3) are referred to as macrophages. Cells negative for both Gr1
and F4/80 were then gated using CD11b and CD11c (Sup. Fig. 1D). Cells positive for
CD11c (Q2 and Q3) are referred to as dendritic cells. CD11b cells (Q1) are referred to
explicitly in the text.

2.7. In vivo bioluminescence imaging
Initial studies employed a luciferase virus to monitor transgene expression over
time. In vivo luciferase expression was monitored using an IVIS imaging system
(Caliper, Alameda, CA). Mice were anesthetized with isoﬂurane and then administered an IP injection of d-luciferin (Caliper) at a dose 150 mg/kg. The animals were
then placed in the imaging chamber, and bioluminescence images were acquired
(every 2 min for a total of 20 min) until the peak light emission was conﬁrmed.
Brightﬁeld images and bioluminescence images were superimposed using the Living
Image software (Caliper). The signal intensity was reported as an integrated light
ﬂux (photons/s) as determined by Living Image Software.

2.8. Statistics
Multiple groups were compared using one-way ANOVA with the Tukey post-hoc
test or by the Friedman test followed by Dunn’s Multiple Comparison Test. All other
comparisons were made with an unpaired t test. The speciﬁc test used is speciﬁed in
each ﬁgure legend. All analysis was carried out using GraphPad Prism.
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Fig. 1. Identiﬁcation of leukocytes inﬁltrating PLG scaffolds. (A) Number of CD45 positive cells isolated from scaffolds at 3, 7, 14, and 21 days. (B) The percentage of CD45 positive
cells that also labeled positive for CD4, Gr1, F4/80, CD11c, CD11b, or CD8. Each mouse received bilateral scaffold implants, n ¼ 4 to 5 mice per group. *P < 0.05 compared to day 3.
#P < 0.05 compared to day 7. Statistics determined by One Way ANOVA with Tukey post-hoc test.

3. Results
3.1. Leukocyte inﬁltration into scaffolds
Initial studies focused on characterizing dynamic leukocyte
populations that inﬁltrate and reside within the microporous PLG
scaffolds. Flow cytometry revealed that leukocytes, identiﬁed by
CD45 expression, inﬁltrated the scaffold by day 3, and their
numbers remained at similar levels through day 21 (Fig. 1A).
However, the types of leukocytes associated with the scaffold
changed during this time frame (Fig. 1B). Cells positive for F4/80, a
macrophage marker, were the most numerous cell type at all time
points, constituting 40% of the total CD45 positive cells at day 3 but
decreasing to 25% by day 21. Similar trends were observed for cells
positive for Gr1 and CD11c, which are markers for neutrophils and

dendritic cells, respectively. In contrast, the proportion of CD4
positive cells signiﬁcantly increased from 7% to 20% over this time
frame, while CD8 positive cells consistently made up less than 5% of
the cells in the scaffold. The remaining cells recovered from the
scaffold were CD11b positive, but not positive for any other markers
investigated. The presence of CD11b positive cells signiﬁcantly
increased from day 3 to day 7 and then returned to day 3 levels.
3.2. Viral vector delivery from scaffolds
We next investigated gene delivery as a means to locally induce
protein production, which would be employed subsequently to
express IL-10. Scaffolds loaded with luciferase lentivirus were
implanted into the right IP fat pad. In vivo bioluminescence imaging
indicated that luciferase expression within the IP fat region (Fig. 2A,

Fig. 2. Level and duration of transgene expression in vivo. (A) Representative bioluminescence images at days 3, 7, and 28 post implantation for scaffolds loaded with luciferase
lentivirus and implanted into the right IP fat pad. Color bar indicates radiance (p/sec/cm2/sr). (B) Total photon ﬂux per second (p/s) from each region of interest (R1, red line; R2,
solid black line; R3, dotted black line), n ¼ 6 mice per group. *P < 0.05 compared to day 1. Statistics determined by the Friedman test followed by Dunn’s Multiple Comparison Test in
which ﬂuxes through each region of interest at each time point were compared to day 1. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to
the web version of this article.)
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Fig. 3. Leukocyte transgene expression within PLG scaffolds at day 3. (A) Representative bivariate dot plots of F4/80 versus tdTomato ﬂuorescence. Thresholds for tdTomato
ﬂuorescence were set relative to cells isolated from scaffolds loaded with luciferase virus. (B) Percentage of F4/80, Gr1, CD11c, and CD4 cells that were also positive for tdTomato
ﬂuorescence. *P < 0.05 compared to Gr1, CD11c, and CD4 positive cells. (C) The tdTomato median ﬂuorescence intensity on F4/80, Gr1, CD11c, and CD4 positive cells. *P < 0.05 versus
CD11c positive cells. Each mouse received bilateral scaffolds implants, n ¼ 5 mice per group. Statistics determined by one-way ANOVA with Tukey post-hoc test.

red line) was at background levels at day 1, but maximal by day 3
and remained at similar levels through day 14 (Fig. 2B, R1). Luciferase expression in the IP fat region was heterogeneous within the
group at days 21 and 28 and average levels were not signiﬁcantly
different from day 1. Luciferase expression was also observed in
regions that correspond anatomically to the spleen (Fig. 2A, solid
black line) and the thymus or lungs (Fig. 2A, dotted black line),
which is consistent with previous reports and likely results from

migration of leukocytes that were transduced at the scaffold to
these tissues [19]. Luciferase expression at these sites was signiﬁcantly above day 1 at days 3 and 7 (Fig. 2B, R2 and R3).
3.3. Leukocyte transgene expression within scaffolds
We subsequently investigated which leukocytes were transduced following lentivirus delivery. Transduced cells were

Fig. 4. Macrophage phenotype on scaffolds in vitro. (A) Total photon ﬂux per second (p/s) measured from RAW macrophages seeded on scaffolds loaded with different doses of
luciferase lentivirus particles (VP) and then treated with luciferin. n ¼ 4. *P < 0.0001 versus 1  107 VP and background. Statistics determined by two-way ANOVA with Bonferroni
post-hoc test. (B) TNF-a and IL-10 production by RAW macrophages seeded on scaffolds loaded with 2  107 VP encoding for IL-10 (vIL-10) or luciferase (vCtrl) and then treated with
LPS (þLPS). Empty scaffold (NT) and no LPS (-LPS) controls were included. Cytokine production measured by ELISA. n ¼ 4e5. *P < 0.001 versus corresponding vCtrl. **P < 0.001
versus vIL-10 (-LPS). Statistics determined by one-way ANOVA with Tukey post-hoc test.

2028

R.M. Gower et al. / Biomaterials 35 (2014) 2024e2031

determined by detection of tdTomato expression by ﬂow cytometry, with the identity of these cells determined by antibody
staining of surface markers (Fig. 3A). Three days after scaffold
implant F4/80, Gr1, CD11c, and CD4 positive cells were positive for
tdTomato expression. Approximately 15 percent of all F4/80 positive cells were positive for tdTomato expression, which was
signiﬁcantly greater than for Gr1, CD11c, and CD4 positive cells that
ranged from 3% to 6% (Fig. 3B). In addition, approximately 13% of
tdTomato positive cells were negative for leukocyte markers indicating other cell types such as adipocytes, ﬁbroblasts, or endothelial
cells were also transduced (data not shown). Interestingly, F4/80
and Gr1 positive cells had the lowest mean ﬂuorescence intensity
for tdTomato, suggesting relatively low levels of protein production
per cell or high levels of protein degradation (Fig. 3C). In contrast,
CD11c positive cells had the greatest ﬂuorescence intensity for
tdTomato per cell.
3.4. Macrophage phenotype on scaffolds in vitro
Gene delivery from PLG scaffolds was subsequently investigated
in vitro to determine if macrophage phenotype could be modulated,
as measured by a reduction in TNF-a production and an increase in
IL-10 production. A lentivirus dose of 2  107 viral particles (VP)
was determined to be necessary for achieving transgene expression
levels that were signiﬁcantly above background (Fig. 4A). Gene
expression by the cells was observed to increase through day 3, and
subsequently decline through day 7. IL-10 lentivirus delivery from
the scaffold, followed by LPS-induction of cytokine production at
day 3 (peak transgene expression), resulted in a signiﬁcant
decrease in TNF-a production relative to no treatment and virus
control (Fig 4B). Furthermore, a signiﬁcant increase in IL-10 production was observed relative to control virus, no treatment, and
LPS negative controls. These data indicate the scaffold based viral
delivery of IL-10 is capable of modulating macrophage cytokine
expression in response to an acute inﬂammatory stimulus.
3.5. Leukocyte inﬁltration into IL-10 virus releasing scaffolds

Fig. 5. Leukocyte inﬁltration into IL-10 virus releasing scaffolds. (A) Number of CD45
positive cells isolated from scaffolds loaded with IL-10 or luciferase virus at day 3 and
day 7 post implantation. *P < 0.05 versus day 7 luciferase. (B) Number of CD4, Gr1, F4/
80, CD11c, CD11b, or CD8 cells isolated from scaffolds loaded with IL-10 or luciferase
virus at day 7. (C) The percentage of CD45 positive cells that were CD4, Gr1, F4/80,
CD11c, CD11b, or CD8 positive at day 7. *P < 0.05 versus luciferase for each cell type.
Each mouse received bilateral scaffolds implants. 5 mice per group. Statistics determined by t-test.

We hypothesized that localized IL-10 expression from the scaffold would modulate the inﬁltration of leukocytes and their
phenotype. At 3 days post implantation of IL-10 lentivirus loaded
scaffolds, the number of leukocytes in the scaffold was not significantly different between the scaffolds loaded with an IL-10 or
luciferase control virus. However, seven days post implantation,
leukocyte inﬁltration signiﬁcantly decreased relative to control
(Fig. 5A). At both time points, the scaffolds loaded with luciferase
virus had similar numbers of leukocytes compared to blank scaffolds (Fig. 1A), indicating that vector delivery did not signiﬁcantly
affect leukocyte inﬁltration. Both the number of F4/80 and Gr1
positive cells was signiﬁcantly decreased on day 7 within scaffolds
loaded with IL-10 virus compared to scaffolds loaded with luciferase virus (Fig. 5B). However, at day 7, the relative percentages of
leukocyte populations were not signiﬁcantly changed for the cell
types investigated, though the greatest trend was a decrease in the
percentage of F4/80 positive cells (Fig. 5C).

(Fig. 6A). Furthermore, in IL-10 releasing scaffolds, F4/80 positive
cells expressed signiﬁcantly more IL-10 than did CD4 and CD11c
positive cells. No signiﬁcant difference in IL-10 expression in CD4
and CD11c positive cells was detected between the two groups. We
next investigated expression of the pro-inﬂammatory cytokines IL1b, IFN-g, and TNF-a (Fig. 6BeD). In scaffolds delivering IL-10, we
observed that CD4, F4/80, and CD11c positive cells expressed
signiﬁcantly less IFN-g compared to cells isolated from control
scaffolds. No signiﬁcant differences in intracellular TNF-a and IL-1b
expression were observed between the two groups; however, TNFa exhibited a decreasing trend for all cell types.

3.6. Cytokine production within IL-10 virus releasing scaffolds

4. Discussion

A hallmark of the host response is inﬂammatory cytokine
expression such as IL-1b, IFN-g, and TNF-a, while resolution of
inﬂammation is characterized by IL-10 expression. Flow cytometry
indicated that F4/80 positive cells isolated from IL-10 releasing
scaffolds had a greater mean ﬂuorescence intensity following IL-10
antibody staining relative to F4/80 positive cells isolated from
luciferase releasing scaffolds, indicating elevated IL-10 expression

The innate immune response to the implanted biomaterials
contributes to the post-injury microenvironment that inﬂuences
the extent of regeneration [1,2]. Excessive inﬂammation can
impede the implant’s integration with the host and tissue regeneration, and can adversely affect the survival and function of cells
delivered by the scaffold [1]. We characterized the host response to
porous PLG scaffolds implanted in the IP fat, an anatomical site that

R.M. Gower et al. / Biomaterials 35 (2014) 2024e2031
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Fig. 6. Cytokine production within IL-10 virus releasing scaffolds. (A) IL-10, (B) IFN-g, (C) IL-1b, and (D) TNF-a expression as measured by median ﬂuorescence intensity (MFI) on
CD4, F4/80, and CD11c positive cells isolated from scaffolds loaded with either luciferase or IL-10 encoding virus. *P < 0.05 for F4/80 positive cell IL-10 expression relative to
luciferase scaffolds by t-test.^P < 0.05 versus bars as indicated with line by one-way ANOVA with Tukey post-hoc test. **P < 0.05 versus luciferase for each cell type by t-test. Each
mouse received bilateral scaffolds implants, n ¼ 5 mice per group.

has been employed for cell transplantation, such as islets for diabetes therapies [25e29]. Multicolor ﬂow cytometry was used to
characterize the kinetics of leukocyte inﬁltration of six major
leukocyte populations within the scaffold at 4 time points postimplant. Leukocytes were present within the scaffold as early as
day 3 and remained at similar numbers through day 21. Macrophages were the most prevalent leukocyte found in the scaffold at
all time points, consistent with previous studies [11,18,20,21,24,30].
The studies herein also quantiﬁed the frequency of other leukocyte
populations, and detected members of the adaptive immune system such as T cells. Thus strategies to modulate inﬂammation, and
ultimately immunity, within biomaterial implants will need to inﬂuence cellular processes (e.g., leukocyte inﬁltration) at or near the
time of implantation.
IL-10 delivery decreased leukocyte numbers within the scaffold,
an effect observed at day 7 but not day 3. The inability to inﬂuence
leukocyte numbers at day 3 likely results from the gene expression
proﬁle of the IL-10, which in vivo bioluminescence imaging suggests was low prior to day 3 and peaks between day 3 and 14. The
decreased leukocyte numbers within the scaffold was primarily
due to a decrease in the number of macrophages. The ability to
decrease macrophage inﬁltration is signiﬁcant in the context of
tissue engineering as their adhesion to biomaterial scaffolds can
result in macrophage activation [31,32]. Macrophage activation
involves the release of cytokines, which recruit and activate additional leukocytes leading to impairment of wound healing [8],
clinical failure of medical devices [33], and the rejection of nonautologous tissue. The signiﬁcance of reduced macrophage inﬁltration is exempliﬁed with studies of islet transplantation. Macrophage inﬁltration into islet grafts results in early rejection, while
systemic macrophage depletion signiﬁcantly improves islet graft
survival [34e36]. A consequence of systemic macrophage depletion
would be an impaired host defense and wound healing [37,38].

Thus, a localized strategy to exclude macrophages from the
biomaterial or transplant site could create a microenvironment
more favorable to survival of transplanted cells while minimizing
the risk of systemic consequences.
A cellular level analysis, enabled by ﬂow cytometry, indicated
that following viral IL-10 delivery from scaffolds, macrophages upregulated IL-10, while macrophages, dendritic cells, and CD4 T cells
down-regulated the production of the inﬂammatory cytokine IFNg. Many studies have characterized bulk cytokine expression within
and around implanted biomaterial scaffolds [6,7,11]. Herein, we
identify the cytokines levels within speciﬁc cell types in situ.
Macrophages were the highest producers of IL-10 following IL-10
gene delivery, which likely contributed to the reduction in leukocyte inﬁltration into the scaffold. Decreased IFN-g levels within
macrophages, dendritic cells, and T cells were observed within
scaffolds inducing IL-10 expression. IFN-g typically converts resting
macrophages into cells with increased capacity for antigen presentation, pro-inﬂammatory cytokine synthesis, and phagocytosis
[39], thus playing a key role in allogeneic tissue rejection [40]. The
ability to modulate both IL-10 and IFN-g production within the
scaffold would be expected to contribute to a more favorable
environment for regeneration or survival and function of transplanted cells.
Leukocytes were transduced directly with delivery of the gene
therapy vector, with macrophages being the most transduced
leukocyte and dendritic cells exhibiting the greatest intracellular
transgene-encoded protein production. Previous studies have reported that both macrophages and dendritic cells exhibit transgene
expression within plasmid [18,24,30] and viral-based [19] gene
releasing scaffolds. Histological analysis identiﬁed these cells
within the scaffold and preferentially located near the polymer
surface, yet histology was unable to identify transgene expression
levels. Despite producing less tdTomato than dendritic cells,
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macrophages were the greatest producer of IL-10 following delivery of the lentivirus encoding IL-10. This discrepancy in protein
production could be due to positive feedback loops present in
macrophages, in which IL-10 signaling induces increased IL-10
production [41]. Viral delivery is also known to transduce nonleukocytes present in and around the scaffold [19,20,42] and our
results here indicate that a subset of tdTomato positive cells were
not leukocytes. Thus adipocytes, ﬁbroblasts, or endothelial cells
present around the scaffolds likely also contributed to IL-10
transgene expression responsible for the leukocyte numbers and
cytokine expression observed within the scaffold.
5. Conclusions
Following scaffold implantation into the intraperitoneal fat,
leukocyte inﬁltration reached maximal levels by day 3-post
implant and remained at similar levels through day 21, with macrophages being the most prevalent cell type within the scaffold at
all time points. Delivery of an IL-10 encoding vector signiﬁcantly
decreased leukocyte inﬁltration, increased macrophage IL-10
expression, and decreased macrophage, dendritic cell, and CD4 T
cell IFN-g expression. Macrophages were the most commonly
transduced leukocyte in this system, while transduced dendritic
cells expressed the highest level of the transgene, indicating that
modulation of leukocyte inﬁltration and IFN-g expression likely
occurred through both autocrine and paracrine signaling mechanisms. This study characterized the role that leukocyte populations
play in modulating the local immune environment following IL-10
expression at tissue engineering scaffolds, which has implications
for the design of combinatorial delivery devices for local
immunomodulation.
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